Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany.
Bone Marrow Transplant. 2012 Aug;47(8):1046-50. doi: 10.1038/bmt.2011.216. Epub 2011 Nov 14.
The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (>2.0 × 10(6) CD34+ cells/kg: 81.6%; >5.0 × 10(6) CD34+ cells/kg: 32.0%) than in NHL patients (>2.0 × 10(6) CD34+ cells/kg: 64.8%; >5.0 × 10(6) CD34+ cells/kg: 12.6%; P<0.0001) and also significantly higher in HL patients (>2.0 × 10(6) CD34+ cells/kg: 81.5%; >5.0 × 10(6) CD34+ cells/kg: 22.2%) than in NHL patients (P=0.013). In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required.
新型造血干细胞动员剂培洛利昔（plerixafor）在 13 个欧洲国家的全国性同情用药项目中进行了疗效评估。共有 580 例非霍奇金淋巴瘤（NHL）、霍奇金淋巴瘤（HL）和多发性骨髓瘤（MM）患者纳入研究。所有患者均接受培洛利昔联合粒细胞集落刺激因子（G-CSF）治疗，且部分患者接受化疗。总体而言，MM 患者（>2.0×106 CD34+细胞/kg：81.6%；>5.0×106 CD34+细胞/kg：32.0%）的采集产量显著高于 NHL 患者（>2.0×106 CD34+细胞/kg：64.8%；>5.0×106 CD34+细胞/kg：12.6%；P<0.0001），HL 患者（>2.0×106 CD34+细胞/kg：81.5%；>5.0×106 CD34+细胞/kg：22.2%）也显著高于 NHL 患者（P=0.013）。亚组分析显示，弥漫性大 B 细胞淋巴瘤、滤泡性淋巴瘤和套细胞淋巴瘤患者之间的动员成功率无显著差异。本研究数据强调了培洛利昔在动员不良患者中的作用，但需要进一步制定提高采集产量的策略，尤其是在 NHL 患者中。
